Welcome!

Wireless Authors: Peter Silva, Kevin Benedict, Carmen Gonzalez, Liz McMillan, Yeshim Deniz

News Feed Item

Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

http://www.reportlinker.com/p0750271/Asia-Pacific-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the Asia-Pacific In Vitro Diagnostics market – Australia, China, India and Japan. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Countries covered include Australia, China, India and Japan.

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.

- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the market categories and countries.

- Global corporate-level profiles of key companies operating within the Asia-Pacific In Vitro Diagnostics market..

- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Sysmex Corporation, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.

- Develop market-entry and market expansion strategies.

- Design competition strategies by identifying who-stands-where in the Asia-Pacific In Vitro Diagnostics competitive landscape.

- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.

- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 11

2 Introduction 13

2.1 What is This Report About? 13

3 In Vitro Diagnostics in Asia-Pacific 14

3.1 In Vitro Diagnostics Cross Country Comparison, Revenue ($m), USD Constant, 2004-2018 14

3.2 In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, 2004-2018 15

3.3 In Vitro Diagnostics, Asia-Pacific, Company share (2010-2011) 23

4 In Vitro Diagnostics In Japan 25

4.1 In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 25

4.2 In Vitro Diagnostics, Japan, Distribution Share (2010-2011) 31

4.3 In Vitro Diagnostics, Japan, Company Share (2010-2011) 35

5 In Vitro Diagnostics In Australia 51

5.1 In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, 2004-2018 51

5.2 In Vitro Diagnostics, Australia, Distribution Share (2010-2011) 57

5.3 In Vitro Diagnostics, Australia, Company Share (2010-2011) 61

6 In Vitro Diagnostics In India 77

6.1 In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, 2004-2018 77

6.2 In Vitro Diagnostics, India, Distribution Share (2010-2011) 83

6.3 In Vitro Diagnostics, India, Company Share (2010-2011) 87

7 In Vitro Diagnostics In China 103

7.1 In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 103

7.2 In Vitro Diagnostics, China, Distribution Share (2010-2011) 109

7.3 In Vitro Diagnostics, China, Company Share (2010-2011) 113

8 Overview of Key Companies in Asia-Pacific In Vitro Diagnostics 129

8.1 F. Hoffmann-La Roche Ltd. 129

8.2 Siemens Healthcare 130

8.3 Abbott Laboratories 131

8.4 Sysmex Corporation 132

8.5 Beckman Coulter, Inc. 133

8.6 Ortho-Clinical Diagnostics Inc. 134

8.7 Becton, Dickinson and Company 135

8.8 Bio-Rad Laboratories, Inc. 135

8.9 bioMerieux S.A. 136

8.10 Eiken Chemical Co.,Ltd. 136

8.11 Shanghai Kehua Bio-engineering Co., Ltd. 137

8.12 Mindray Medical International Limited 137

8.13 Alere Inc. 138

8.14 Transasia Bio-Medicals Ltd. 138

8.15 Nihon Kohden Corporation 139

8.16 Horiba, Ltd. 139

8.17 Qiagen N.V. 140

8.18 DiaSorin S.p.A 140

8.19 PerkinElmer, Inc. 141

8.20 Tosoh Corporation 141

8.21 Danaher Corporation 142

8.22 Thermo Fisher Scientific Inc. 142

8.23 Gen-Probe Incorporated 143

8.24 Span Diagnostics Ltd. 143

8.25 Diagnostica Stago, Inc. 143

8.26 Agappe Diagnostics Ltd. 144

8.27 Life Technologies Corporation 144

8.28 Grifols, S.A. 145

8.29 Trivitron Healthcare Pvt Ltd. 145

8.30 Himedia Laboratories Pvt. Ltd. 145

8.31 Tulip Diagnostics (P) Ltd 146

9 In Vitro Diagnostics Market Pipeline Products 147

9.1 Clinical Chemisty Market Pipeline Products 147

9.2 Immuno Chemistry Market Pipeline Products 150

9.3 Haematology Market Pipeline Products 160

9.4 Infectious Immunology Market Pipeline Products 162

9.5 Microbiology Culture Market Pipeline Products 169

9.6 Histology And Cytology Market Pipeline Products 170

9.7 Genetic Testing Market Pipeline Products 171

10 Financial Deals Landscape 176

10.1 Merger 176

10.2 Acquisition 178

10.3 Partnerships 187

11 Recent Developments 273

11.1 Strategy And Business Planning 273

11.2 Research And Development 279

11.3 Government and Public Interest 282

11.4 Product News 285

12 Appendix 299

12.1 Definitions of Markets Covered in the Report 300

12.2 Research Methodology 301

12.3 Secondary Research 301

12.4 Primary Research 302

12.5 Models 302

12.6 Forecasts 303

12.7 Expert Panels 303

12.8 GlobalData Consulting 303

12.9 Currency Conversion 304

12.10 Contact Us 304

12.11 Disclaimer 304

List of Tables

Table 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-2018 21

Table 2: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, 2004-2018 23

Table 3: In vitro diagnostics, Asia-Pacific, Cross-Category Analysis, 2004-2018 25

Table 4: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, Historic, 2004-2011 27

Table 5: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 29

Table 6: In Vitro Diagnostics, Asia-Pacific, Company share by Revenue ($m), USD Constant, 2010-2011 31

Table 7: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 33

Table 8: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-2011 35

Table 9: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 37

Table 10: Clinical Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 38

Table 11: Genetic Testing, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 38

Table 12: Haematology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 39

Table 13: Histology And Cytology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 39

Table 14: Immuno Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 40

Table 15: Infectious Immunology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 40

Table 16: Microbiology Culture, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 41

Table 17: In Vitro Diagnostics, Japan, Company Share, USD Constant, (2010-2011) 43

Table 18: Clinical Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 45

Table 19: Genetic Testing, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 47

Table 20: Haematology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 49

Table 21: Histology And Cytology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 51

Table 22: Immuno Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 53

Table 23: Infectious Immunology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 55

Table 24: Microbiology Culture, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 57

Table 25: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, 2004-2018 59

Table 26: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, Historic, 2004-2011 61

Table 27: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 63

Table 28: Clinical Chemistry, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 64

Table 29: Genetic Testing, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 64

Table 30: Haematology, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 65

Table 31: Histology And Cytology, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 65

Table 32: Immuno Chemistry, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 66

Table 33: Infectious Immunology, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 66

Table 34: Microbiology Culture, Australia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 67

Table 35: In Vitro Diagnostics, Australia, Company Share, USD Constant, (2010-2011) 69

Table 36: Clinical Chemistry, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 71

Table 37: Genetic Testing, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 73

Table 38: Haematology, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 75

Table 39: Histology And Cytology, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 77

Table 40: Immuno Chemistry, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 79

Table 41: Infectious Immunology, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 81

Table 42: Microbiology Culture, Australia, Company Share by Revenue ($m), USD Constant, 2010-2011 83

Table 43: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, 2004-2018 85

Table 44: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, Historic, 2004-2011 87

Table 45: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 89

Table 46: Clinical Chemistry, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 90

Table 47: Genetic Testing, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 90

Table 48: Haematology, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 91

Table 49: Histology And Cytology, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 91

Table 50: Immuno Chemistry, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 92

Table 51: Infectious Immunology, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 92

Table 52: Microbiology Culture, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 93

Table 53: In Vitro Diagnostics, India, Company Share by Revenue ($m), USD Constant, 2010-2011 95

Table 54: Clinical Chemistry, India, Company Share by Revenue ($m), USD Constant, 2010-2011 97

Table 55: Genetic Testing, India, Company Share by Revenue ($m), USD Constant, 2010-2011 99

Table 56: Haematology, India, Company Share by Revenue ($m), USD Constant, 2010-2011 101

Table 57: Histology And Cytology, India, Company Share by Revenue ($m), USD Constant, 2010-2011 103

Table 58: Immuno Chemistry, India, Company Share by Revenue ($m), USD Constant, 2010-2011 105

Table 59: Infectious Immunology, India, Company Share by Revenue ($m), USD Constant, 2010-2011 107

Table 60: Microbiology Culture, India, Company Share by Revenue ($m), USD Constant, 2010-2011 109

Table 61: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 111

Table 62: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Historic, 2004-2011 113

Table 63: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 115

Table 64: Clinical Chemistry, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 116

Table 65: Genetic Testing, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 116

Table 66: Haematology, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 117

Table 67: Histology And Cytology, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 117

Table 68: Immuno Chemistry, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 118

Table 69: Infectious Immunology, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 118

Table 70: Microbiology Culture, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011 119

Table 71: In Vitro Diagnostics, China, Company Share, USD Constant, (2010-2011) 121

Table 72: Clinical Chemistry, China, Company Share by Revenue ($m), USD Constant, 2010-2011 123

Table 73: Genetic Testing, China, Company Share by Revenue ($m), USD Constant, 2010-2011 125

Table 74: Haematology, China, Company Share by Revenue ($m), USD Constant, 2010-2011 127

Table 75: Histology And Cytology, China, Company Share by Revenue ($m), USD Constant, 2010-2011 129

Table 76: Immuno Chemistry, China, Company Share by Revenue ($m), USD Constant, 2010-2011 131

Table 77: Infectious Immunology, China, Company Share by Revenue ($m), USD Constant, 2010-2011 133

Table 78: Microbiology Culture, China, Company Share by Revenue ($m), USD Constant, 2010-2011 135

Table 79: Clinical Chemisty Market Pipeline Products 154

Table 80: Immuno Chemistry Market Pipeline Products 157

Table 81: Haematology Market Pipeline Products 167

Table 82: Infectious Immunology Market Pipeline Products 169

Table 83: Microbiology Culture Market Pipeline Products 176

Table 84: Histology And Cytology Market Pipeline Products 177

Table 85: Genetic Testing Market Pipeline Products 178

Table 86: Nabi Biopharma Completes Merger With Biota 183

Table 87: Genting Invests $32 Million In TauRx Pharma 185

Table 88: PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech For $38 Million 186

Table 89: SK Telecom To Acquire 49% Stake In Xi'an Tianlong, In-vitro Diagnostics Company 188

Table 90: Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 189

Table 91: Wuhan Humanwell Hi-tech Industry To Acquire 80% Stake In Beijing Baron Medical Equipment For $123 Million 190

Table 92: OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology, Pathology Testing Products Provider 191

Table 93: Shanghai Fosun Pharma Acquires 17.65% Stake In SD Biosensor, In Vitro Diagnostics Company 192

Table 94: Mindray Medical Completes Acquisition Of Controlling Stake In Hunan Changsha Tiandiren Biotech For $3 Million 193

Table 95: Swift Biosciences Enters Into Licensing Agreement With Vela Diagnostics For Cancer Detection Technology 194

Table 96: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay 195

Table 97: Institute of Microelectronics Enters Into Co-Development Agreement With SFC Fluidics 197

Table 98: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant Systems For High Pressure Technologies 198

Table 99: Takara Bio Enters Into Co-Marketing Agreement With Pathogenica For HAI Sequencing Service 199

Table 100: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 200

Table 101: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 202

Table 102: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 203

Table 103: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 204

Table 104: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 205

Table 105: BG Medicine Enters Into Agreement With Wuhan Kindstar Diagnostics For Galectin-3 Testing 206

Table 106: BioDot Enters Into Co-Marketing Agreement With JOT Automation 207

Table 107: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 208

Table 108: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 209

Table 109: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 210

Table 110: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 211

Table 111: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 212

Table 112: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 213

Table 113: CML HealthCare Enters Into Agreement With MaRS Innovation 214

Table 114: Akrivis Technologies Enters Into Co-Development Agreement With United States Biological 215

Table 115: Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 216

Table 116: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 217

Table 117: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 218

Table 118: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 219

Table 119: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 220

Table 120: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 221

Table 121: Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology Agency For Microdroplet Generation Technology 222

Table 122: Edan Instruments And Edan Diagnostics Form Joint Venture With Xizeng Shi 223

Table 123: NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For Oncotype DX Tests 224

Table 124: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 226

Table 125: DiaSorin Forms Joint Venture With Trivitron Healthcare 227

Table 126: Ahn-Gook Pharma Enters Into Licensing Agreement With Ceragem Medisys 228

Table 127: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 229

Table 128: Agilent Enters Into Co-Development Agreement With Gachon University For Biomarkers 230

Table 129: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 231

Table 130: Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems 232

Table 131: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 233

Table 132: Molecular Discovery Enters Into Co Development Agreement With Peter MacCallum Cancer Centre 234

Table 133: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 235

Table 134: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 236

Table 135: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 237

Table 136: Immuno-Biological Labs To Form Joint Venture With TransGenic 238

Table 137: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 239

Table 138: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test 240

Table 139: One Lambda Enters Into Co-Marketing Agreement With CellTrend 241

Table 140: Fujitsu Taiwan Enters Into Co-Development Agreement With National Cheng Kung University 242

Table 141: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientific and Industrial Research 243

Table 142: Trovagene Enters Into Licensing Agreement With Strand Life Sciences For HPV Test 244

Table 143: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 245

Table 144: Insight Genetics Enters Into Licensing Agreement With Kindstar Globalgene Technology For ALK Screen Biomaker 246

Table 145: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 247

Table 146: AITbiotech Enters Into Licensing Agreement With Exploit Technologies For H5N1 Test Kit 248

Table 147: Seegene Enters Into Co-Development Agreement With DuPont Nutrition & Health To Develop Multiplexed Assays For Food Safety Testing 249

Table 148: Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical Technology 250

Table 149: Everist Genomics Enters Into Joint Venture Agreement With Manipal Group 251

Table 150: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 252

Table 151: Pacific Biosciences Enters Into Co-Marketing Agreement With Tomy Digital Biology 253

Table 152: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 254

Table 153: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 255

Table 154: HealthLinx Enters Into Distribution Agreement With INEX Innovations Exchange And Metropolis Healthcare For OvPlex 256

Table 155: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 257

Table 156: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 258

Table 157: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology 259

Table 158: Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University For New Cancer Biomarkers 260

Table 159: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 261

Table 160: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System 262

Table 161: Metabolon Enters Into Co-Development Agreement With Takeda Pharma 263

Table 162: GE Healthcare Enters Into Research Agreement With Clino 264

Table 163: Sysmex Extends Distribution Agreement With Roche 265

Table 164: NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 266

Table 165: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 267

Table 166: Molecular Response Enters Into Co-Marketing Agreement With Transparent 268

Table 167: A*STAR Enters Into Co-Development Agreement With QuantuMDx Group 269

Table 168: Epistem Holdings Enters Into Co-Marketing Agreement With Xcelris Labs For Molecular Tuberculosis Diagnostic Test 270

Table 169: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 271

Table 170: Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 272

Table 171: SQI Diagnostics Enters Into Distribution Agreement With Integrated Sciences 273

Table 172: Avesthagen Enters Into Co-Development Agreement With CosmosID 274

Table 173: GeneNews Forms Joint Venture With Shanghai Biochip For Sentinel Centre For Personalized Medicine 275

Table 174: Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 277

Table 175: ZyGEM Enters Into Co-Development Agreement With USAMRIID 278

Table 176: BioTime Enters Into Distribution Agreement With USCN Life Science 279

List of Figures

Figure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-2018 21

Figure 2: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, 2004-2018 22

Figure 3: In Vitro Diagnostics, Asia-Pacific, Cross-Category Analysis, 2004-2018 24

Figure 4: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, Historic, 2004-2011 26

Figure 5: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 28

Figure 6: In Vitro Diagnostics, Asia-Pacific, Company share (%), 2011 30

Figure 7: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 32

Figure 8: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-2011 34

Figure 9: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 36

Figure 10: In Vitro Diagnostics, Japan, Company Share (%), 2011 42

Figure 11: Clinical Chemistry, Japan, Company Share (%), 2011 44

Figure 12: Genetic Testing, Japan, Company Share (%), 2011 46

Figure 13: Haematology, Japan, Company Share (%), 2011 48

Figure 14: Histology And Cytology, Japan, Company Share (%), 2011 50

Figure 15: Immuno Chemistry, Japan, Company Share (%), 2011 52

Figure 16: Infectious Immunology, Japan, Company Share (%), 2011 54

Figure 17: Microbiology Culture, Japan, Company Share (%), 2011 56

Figure 18: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, 2004-2018 58

Figure 19: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, Historic, 2004-2011 60

Figure 20: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 62

Figure 21: In Vitro Diagnostics, Australia, Company Share (%), 2011 68

Figure 22: Clinical Chemistry, Australia, Company Share (%), 2011 70

Figure 23: Genetic Testing, Australia, Company Share (%), 2011 72

Figure 24: Haematology, Australia, Company Share (%), 2011 74

Figure 25: Histology And Cytology, Australia, Company Share (%), 2011 76

Figure 26: Immuno Chemistry, Australia, Company Share (%), 2011 78

Figure 27: Infectious Immunology, Australia, Company Share (%), 2011 80

Figure 28: Microbiology Culture, Australia, Company Share (%), 2011 82

Figure 29: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, 2004-2018 84

Figure 30: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, Historic, 2004-2011 86

Figure 31: In Vitro Diagnostics, India, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 88

Figure 32: In Vitro Diagnostics, India, Company Share (%), 2011 94

Figure 33: Clinical Chemistry, India, Company Share (%), 2011 96

Figure 34: Genetic Testing, India, Company Share (%), 2011 98

Figure 35: Haematology, India, Company Share (%), 2011 100

Figure 36: Histology And Cytology, India, Company Share (%), 2011 102

Figure 37: Immuno Chemistry, India, Company Share (%), 2011 104

Figure 38: Infectious Immunology, India, Company Share (%), 2011 106

Figure 39: Microbiology Culture, India, Company Share (%), 2011 108

Figure 40: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 110

Figure 41: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Historic, 2004-2011 112

Figure 42: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 114

Figure 43: In Vitro Diagnostics, China, Company Share (%), 2011 120

Figure 44: Clinical Chemistry, China, Company Share (%), 2011 122

Figure 45: Genetic Testing, China, Company Share (%), 2011 124

Figure 46: Haematology, China, Company Share (%), 2011 126

Figure 47: Histology And Cytology, China, Company Share (%), 2011 128

Figure 48: Immuno Chemistry, China, Company Share (%), 2011 130

Figure 49: Infectious Immunology, China, Company Share (%), 2011 132

Figure 50: Microbiology Culture, China, Company Share (%), 2011 134

Figure 51: F. Hoffmann-La Roche Ltd., Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 136

Figure 52: Siemens Healthcare, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 137

Figure 53: Abbott Laboratories, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 138

Figure 54: Sysmex Corporation, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 139

Figure 55: Beckman Coulter, Inc., Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 140

Figure 56: Ortho-Clinical Diagnostics Inc., Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2011 141

Companies Mentioned

F. Hoffmann-La Roche Ltd.

Siemens Healthcare

Abbott Laboratories

Sysmex Corporation

Beckman Coulter, Inc.

Ortho-Clinical Diagnostics Inc.

Becton, Dickinson and Company

Bio-Rad Laboratories, Inc.

bioMerieux S.A.

Eiken Chemical Co.,Ltd.

Shanghai Kehua Bio-e

To order this report:

In_Vitro_Diagnostic Industry: Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...
Innodisk is a service-driven provider of industrial embedded flash and DRAM storage products and technologies, with a focus on the enterprise, industrial, aerospace, and defense industries. Innodisk is dedicated to serving their customers and business partners. Quality is vitally important when it comes to industrial embedded flash and DRAM storage products. That’s why Innodisk manufactures all of their products in their own purpose-built memory production facility. In fact, they designed and built their production center to maximize manufacturing efficiency and guarantee the highest quality of our products.
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. Over the summer Gartner released its much anticipated annual Hype Cycle report and the big news is that Internet of Things has now replaced Big Data as the most hyped technology. Indeed, we're hearing more and more about this fascinating new technological paradigm. Every other IT news item seems to be about IoT and its implications on the future of digital business.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. Download Slide Deck: ▸ Here
BSQUARE is a global leader of embedded software solutions. We enable smart connected systems at the device level and beyond that millions use every day and provide actionable data solutions for the growing Internet of Things (IoT) market. We empower our world-class customers with our products, services and solutions to achieve innovation and success. For more information, visit www.bsquare.com.
With the iCloud scandal seemingly in its past, Apple announced new iPhones, updates to iPad and MacBook as well as news on OSX Yosemite. Although consumers will have to wait to get their hands on some of that new stuff, what they can get is the latest release of iOS 8 that Apple made available for most in-market iPhones and iPads. Originally announced at WWDC (Apple’s annual developers conference) in June, iOS 8 seems to spearhead Apple’s newfound focus upon greater integration of their products into everyday tasks, cross-platform mobility and self-monitoring. Before you update your device, here is a look at some of the new features and things you may want to consider from a mobile security perspective.